Tonix reports Q2 2026 results, TONMYA sales rise 197%, HORIZON trial begins

Tonix Pharmaceuticals Holding Corp. reported second quarter 2026 results on August 10, 2026, covering the period ended June 30, 2026. TONMYA net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter, while commercial and government payer coverage expanded to reach approximately 136 million covered lives, or 43% of total U.S. lives.¹

On the pipeline side, the company enrolled its first patient in the Phase 2 HORIZON study of TNX-102 SL for major depressive disorder.¹ The study is expected to enroll approximately 360 patients at about 30 U.S. sites, with a primary endpoint of change from baseline in MADRS total score at Week 6.¹

For Lyme disease prevention, TNX-4800, a Phase 2-ready long-acting anti-OspA monoclonal antibody, is expected to begin an adaptive Phase 2 field study in the first quarter of 2027, contingent on final FDA review and agreement on the study design, after the company received final minutes from a Type C meeting with the FDA in early third quarter 2026.¹ The study will be randomized, double-blind, and placebo-controlled, with a primary endpoint of protection through six months, testing two 450 mg subcutaneous doses given at Day 1 and Day 85 in Lyme-endemic U.S. adults.¹

On the commercial side, the company expects to add 50 new sales representatives by September 2026, bringing its sales force to about 150 people.¹

Financially, Tonix had approximately $176.2 million in cash and cash equivalents as of June 30, 2026, down from about $207.6 million at the end of 2025.¹ The company said its cash, together with proceeds raised from equity offerings in the third quarter of 2026 to date, is expected to fund planned operations into the early second quarter of 2027.¹